Long-term care of the heart transplant recipient

Current Opinion in Organ Transplantation

Volumn 19, Issue 5, 2014, Pages 515-524

  Kittleson, Michelle M ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiac allograft vasculopathy; Heart transplantation; Infection; Malignancy; Rejection

Indexed keywords

ATOVAQUONE; BORTEZOMIB; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CORONARY ARTERY DISEASE; COUNTERPULSATION; DIABETES MELLITUS; DYSLIPIDEMIA; EXTRACORPOREAL OXYGENATION; GENE EXPRESSION PROFILING; GOUT; GRAFT INFECTION; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFECTION PREVENTION; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; OSTEOPOROSIS; PLASMAPHERESIS; REVIEW; SURGICAL MORTALITY; ADVERSE EFFECTS; ALLOGRAFT; GRAFT REJECTION; NEOPLASMS;

ALLOGRAFTS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; LONG-TERM CARE; NEOPLASMS; TRANSPLANT RECIPIENTS;

EID: 84925819242     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000117     Document Type: Review

References (80)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation 2009;119:e391.
2. Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-focus theme: age. J Heart Lung Transplant 2013;32:951.
3. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant 2010;29:1089.
4. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710.
5. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990;9:587.
6. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011;30:252. Timely overview of the current state-of-the-art management of AMR.
7. Kittleson MM, Kobashigawa JA. Antibody-mediated rejection. Curr Opin Organ Transplant 2012;17:551-557.
8. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibodymediated rejection in heart transplant recipients. J Heart Lung Transplant 2013;32:98. Elegant analysis of the impact of anti-HLA antibody strength on outcomes after transplantation.
9. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369:1215.
10. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150.
11. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010;362:1890.
12. Chang DH, Kittleson MM, Kobashigawa JA. Immunosuppression following heart transplantation: prospects and challenges. Immunotherapy 2014;6:181-194.
13. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6:1377.
14. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006;25:434.
15. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694.
16. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847.
17. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48.
18. Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol 1993;21:1142.
19. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibodymediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009;28:417.
20. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006;25:1277.
21. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 2009;28:781.
22. Arbustini E, Roberts WC. Morphological observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease). Am J Cardiol 1996;78:814.
23. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004;19:166.
24. Kittleson MM, Patel JK, Moriguchi JD, et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J Heart Lung Transplant 2011;30:1250.
25. Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon 2011;9:160.
26. Patel J, Everly M, Chang D, et al. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 2011;30:1320. One of the first studies documenting the benefit of bortezomib in highly sensitized patients awaiting transplantation.
27. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006;25:283.
28. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac transplant research database. J Heart Lung Transplant 1998;17:744.
29. Syeda B, Roedler S, Schukro C, et al. Transplant coronary artery disease: incidence, progression and interventional revascularization. Int J Cardiol 2005;104:269.
30. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005;45:1532.
31. Potluri SP, Mehra MR, Uber PA, et al. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. J Heart Lung Transplant 2005;24:1019.
32. Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest 2000;118:1792.
33. Kittleson MM, Kobashigawa JA. Management of the ACC/AHA Stage D patient: cardiac transplantation. Cardiol Clin 2014;32:95-112.
34. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991;324:1791.
35. Ramsdale DB, Bellamy CM. Angina and threatened acute myocardial infarction after cardiac transplantation. Am Heart J 1990;119:1195.
36. Schroeder JS, Hunt SA. Chest pain in heart-transplant recipients. N Engl J Med 1991;324:1805.
37. Gao SZ, Schroeder JS, Hunt SA, et al. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol 1989;64:1093.
38. Uretsky BF, Kormos RL, Zerbe TR, et al. Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Lung Transplant 1992;11:S45.
39. Ahsan N. Chronic allograft failure: natural history, pathogenesis, diagnosis and management. Austin, TX: Landes Bioscience; 2007.
40. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999;14:140.
41. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 1998;98:2672.
42. Rickenbacher P. Role of intravascular ultrasound versus angiography for diagnosis of graft vascular disease. Transplant Proc 1998;30:891.
43. Konig A, Theisen K, Klauss V. Intravascular ultrasound for assessment of coronary allograft vasculopathy. Z Kardiol 2000;89(Suppl 9): IX/45.
44. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621.
45. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013;13:1203. Recent randomized controlled trial of everolimus versus mycophenolate in heart transplantation.
46. Sharifi M, Siraj Y, O'Donnell J, Pompili VJ. Coronary angioplasty and stenting in orthotopic heart transplants: a fruitful act or a futile attempt? Angiology 2000;51:809.
47. Tanaka K, Li H, Curran PJ, et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol 2006;97:1192.
48. Simpson L, Lee EK, Hott BJ, et al. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant 2005;24:1211.
49. Smith JA, Ribakove GH, Hunt SA, et al. Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant 1995;14:832.
50. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003;17:77.
51. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663.
52. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant 2011;29:504.
53. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12:S328.
54. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10:248.
55. Fortina AB, Caforio AL, Piaserico S, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000;19:249.
56. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177.
57. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005;352:1371.
58. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimustreated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18:446.
59. Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385.
60. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77:760.
61. Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125:1747.
62. Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003;49:397.
63. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514.
64. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody okt3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723.
65. Walker RC. Pretransplant assessment of the risk for posttransplant lymphoproliferative disorder. Transplant Proc 1995;27:41.
66. Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001;19:696.
67. Kansara P, Kobashigawa JA. Management of heart transplant recipients: reference for primary care physicians. Postgrad Med 2012;124:215-224.
68. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997;63:664.
69. Zietse R, Balk AH, Vd Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994;14:1.
70. Gustafsson F, Ross HJ. Renal-sparing strategies in cardiac transplantation. Curr Opin Organ Transplant 2009;14:566-570.
71. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1.
72. Frohlich ED, Ventura HO, Ochsner JL. Arterial hypertension after orthotopic cardiac transplantation. J Am Coll Cardiol 1990;15:1102.
73. Starling RC, Cody RJ. Cardiac transplant hypertension. Am J Cardiol 1990;65:106.
74. Hausberg M, Barenbrock M, Hohage H, et al. Ace inhibitor versus betablocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999;33:862.
75. Sennesael J, Lamote J, Violet I, et al. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995;26:436.
76. Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a doubleblind randomised comparative trial. Clin Transplant 2001;15:426.
77. Brozena SC, Johnson MR, Ventura H, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. J Am Coll Cardiol 1996;27:1707.
78. Lindenfeld J, Page RL 2nd, Zolty R, et al. Drug therapy in the heart transplant recipient: part iii: common medical problems. Circulation 2005;111:113.
79. Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part iv: drug-drug interactions. Circulation 2005;111:230.
80. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006;25:1063.